In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CDRH “Innovation Initiative” Highlights Efforts To Speed Premarket Process

This article was originally published in The Gray Sheet

Executive Summary

FDA seeks to underscore its commitment to help innovative new medical devices get to market more quickly with a report unveiled May 22

You may also be interested in...

Imaging Is Key To Product Development In Critical Path Opportunities List

Imaging techniques hold "vast potential" to help speed the development of new medical products, FDA says in the latest report on its Critical Path initiative

MDUFMA II Should Address Pre-IDE Process, Cycle Goals – Stakeholders

FDA should work to improve the process by which companies and the agency negotiate clinical trial designs, several participants argued at the third annual MDUFMA stakeholder meeting Nov. 17

McClellan’s FDA Legacy? Decisive Role In Product Development Priorities

FDA's "critical path" initiative to help streamline R&D costs and product development schedules is positioning the agency to eventually seek grant-making authority from Congress

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts